Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative effects against 22RV1 and PC3 prostate carcinoma cell lines

Seohyun Sona College of Pharmacy, BK21 FOUR Team and Integrated Research Institute for Drug Development, Dongguk University-Seoul, Goyang, Republic of KoreaView further author information

Ahmed Elkamhawya College of Pharmacy, BK21 FOUR Team and Integrated Research Institute for Drug Development, Dongguk University-Seoul, Goyang, Republic of Korea;b Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, EgyptView further author information

Anam Rana Gulc Department of Chemistry, Research Institute of Chem-Bio Diagnostic Technology, Chung-Ang University, Seoul, Republic of KoreaView further author information

Ahmed A. Al‐Karmalawyd Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ahram Canadian University, Giza, Egypt

https://orcid.org/0000-0002-8173-6073 View further author information

Radwan Alnajjare Department of Chemistry, Faculty of Science, University of Benghazi, Benghazi, Libya;f Faculty of Pharmacy, Libyan International Medical University, Benghazi, Libya;g Department of Chemistry, University of Cape Town, Rondebosch, South AfricaView further author information

Ahmed Abdeenh Department of Forensic Medicine and Toxicology, Faculty of Veterinary Medicine, Benha University, Toukh, EgyptView further author information

Samah F. Ibrahimi Department of Clinical Sciences, College of Medicine, Princess Nourah bint Abdulrahman University, Riyadh, Saudi ArabiaView further author information

Saud O. Alshammarij Department of Plant Chemistry and Natural Products, Faculty of Pharmacy, Northern Border University, Arar, Saudi ArabiaView further author information

Qamar A. Alshammarik Department of Pharmacology and Toxicology, Faculty of Pharmacy, Northern Border University, Arar, Saudi ArabiaView further author information

Won Jun Choia College of Pharmacy, BK21 FOUR Team and Integrated Research Institute for Drug Development, Dongguk University-Seoul, Goyang, Republic of KoreaView further author information

Tae Jung Parkc Department of Chemistry, Research Institute of Chem-Bio Diagnostic Technology, Chung-Ang University, Seoul, Republic of KoreaCorrespondence[email protected]
View further author information

Kyeong Leea College of Pharmacy, BK21 FOUR Team and Integrated Research Institute for Drug Development, Dongguk University-Seoul, Goyang, Republic of KoreaCorrespondence[email protected]
View further author information

show all

Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative effects against 22RV1 and PC3 prostate carcinoma cell lines

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative effects against 22RV1 and PC3 prostate carcinoma cell lines

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date